Zhao XZ, Zhang W, Cao Y, et al. Int J Nanomedicine. 2020;15:3953–3964.
The authors have advised due to an error that occurred inadvertently at the time of figure assembly, Figure 2M on page 3956 is incorrect.
Figure 3.
LIP3 bimodal imagining in vitro. (A) LIP3 CEUS imaging and grey value histogram of different groups in vitro. (B) LIP3 PA imaging and PA value scatter diagram with different concentrations in vitro.
The correct Figure 2 is shown below.
The authors have also advised there is an error in Figure 3 on page 3960. The concentration units in part B show “mg” they should read “mg/ml”.
The correct Figure 3 is shown below.
The authors apologize for these errors.
Figure 2.
Continue
Figure 2.
General physicochemical properties of LIP3. (A) Structure illustration of LIP0, LIP1, LIP2, and LIP3. (B) TEM of LIP3. (C) Phasing sign TEM of LIP3. (D) Light microscopy image of LIP3. (E) Fluorescence microscope image of DiI-stained LIP3 NPs (×400). (F) Zeta potential of LIP1, LIP2, and LIP3. (G) Size of LIP1, LIP2, and LIP3. (H) LIP3 light microscopy image of the sonogenic phase transition (× 400). (I) Correlation between concentration of AQ4N and absorbance. (J) Correlation between concentration of HMME and absorbance. (K) UV-vis–NIR absorbance spectra of LIP1, LIP2, and LIP3 and free HMME, AQ4N. (L) Relative production of active oxygen of LIP3. (M) LIP3 size distribution with prolonged time duration. Insert: digital photos of the LIP3 NPs dispersed in PBS (2.5 mg/mL).